Research Interests:

Matthew Baggott, PhD, is interested in the relationships between emotion, decision-making, and behavior. He often approaches this topic by studying how people differ in their responses to pictures and computerized tasks and how these responses are changed by drugs. Much of his research has focused on the effects of serotonergic drugs, particularly MDMA (Ecstasy) and hallucinogens. These studies have been split between investigating the short-term emotional and experiential effects of these drugs, on the one hand, and their basic mechanisms and potential for harm, on the other. He is currently investigating genetic influences on how people deal with success and failure. He earned a PhD in neuroscience from the University of California Berkeley and is currently a postdoctoral fellow in psychiatric genetics at the University of Chicago. You can also find him online at http://gplus.to/mattbaggott.

Awards & Honors:

Presidential Trainee Award, American Society for Clinical Pharmacology and Therapeutics (2009, 2008)

Fellow at the Summer Institute in Cognitive Neuroscience, Dartmouth College, New Hampshire (2006)

Scientific Fellow at the Mind and Life Summer Institute, Garrison, New York (2006)

Recipient Institutional NRSA - NIH Fellowship Institute of Cognitive and Brain Sciences, University of California, Berkeley (2003-6)

Selected Publications:

Galloway GP, Buscemi R, Coyle JR, Flower K, Siegrist JD, Fiske LA, Li L, Baggott MJ, Polcin D, Chen CYA, & Mendelson JE (2011). A randomized, placebo-controlled trial of sustained release dextroamphetamine for methamphetamine addiction. Clinical Pharmacology and Therapeutics, 89, 276-282. PMID: 21178989

Mendelson JE, Coyle JR, Lopez JC, Baggott MJ, Flower K, Everhart ET, Munro TA, Galloway GP, & Cohen BM (2011). Lack of effect of sublingual Salvinorin A, a naturally occurring kappa opioid, in humans: A placebo controlled trial. Psychopharmacology. 214(4):933-9. PMID: 21140258

Li L, Lopez JC, Galloway G, Baggott MJ, Everhart T, Mendelson J (2010). Estimating the intake of abused methamphetamine using experimenter-administered deuterium labeled R-methamphetamine: Selection of the R-methamphetamine dose. Therapeutic Drug Monitoring, 32(4):504-7. PMID: 20592647

Baggott MJ, Siegrist JD, Galloway GP, Robertson LC, Coyle JR, & Mendelson J (2010). Investigating the mechanisms of hallucinogen-induced visions using 3,4-Methylenedioxyamphetamine (MDA) in humans: a controlled clinical trial. PLoS One, published online December 2, 2010. PMID: 21152030

Baggott MJ, Coyle JR, Erowid E, Erowid F, & Robertson LC (2010). Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire. Drug and Alcohol Dependence, preprint online. PMID: 21035275.

Baggott MJ, Erowid E, Erowid F, Galloway GP, & Mendelson J (2010). Use patterns and self-reported effects of Salvia divinorum: An Internet-based survey. Drug and Alcohol Dependence, 111(3):250-6. PMID: 20627425.

Galloway GP, Singleton EG, Buscemi R, Baggott MJ, Dickerhoof RM, Mendelson JE, The Methamphetamine Treatment Project Corporate Authors (2010). An examination of drug craving over time in abstinent methamphetamine users. The American Journal on Addictions. 19(6):510-4.PMID:20958846

Flower K, Li L, Chen CY, Baggott MJ, Galloway GP, & Mendelson J (2010). Efficacy, safety, and ethics of cosmetic neurology far from settled. Clinical Pharmacology and Therapeutics, 88(4):461-3. PMID: 20856245.

Mendelson J, Tolliver BK, Delucchi KL, Baggott MJ, Flower K, Harris CW, Galloway GP, Berger P (2009). Capsaicin, an active ingredient in pepper sprays, increases the lethality of cocaine. Journal of Forensic Toxicology, ePub October 2, 2009. DOI 10.1007/s11419-009-0079-9

Connelly WM & Baggott MJ (2009). Role of endocannabinoids in 5-HT2 receptor-mediated effects. Journal of Neurophysiology, 101(1):5-7. PMID: 19004992.

Baggott M (2002). Preventing problems in ecstasy users: reduce use to reduce harm. J Psychoactive Drugs 34:145-162. PMID: 12691205

Bonson K & Baggott M (2002). Emerging drugs of abuse, in EJ Massaro (Ed.), Handbook of Neurotoxicology, Volume 2, pp. 223-257, Totowa, NJ: Humana Press. ISBN: 0896037967.

Baggott M & Mendelson J (2001). Does MDMA cause brain damage? In J. Holland (Ed.), Ecstasy: the complete guide, pp. 110-145, Rochester, VT: Park Street Press. ISBN: 0892818573.

Harris DS, Baggott M, Mendelson JH, Mendelson JE, & Jones RT (2002). Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology, 162(4):396-405. PMID: 12172693.

Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, & Mendelson J (2000). Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Annals of Internal Medicine, 133(12):969-73. PMID: 11119398.

Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, & Zehnder J (2000). Chemical analysis of ecstasy pills. JAMA, 284(17):2190. PMID: 11056589.